928337-00-2

Basic information

• Product Name: 6-chloro-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine
• Synonyms: 6-chloro-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine
• CAS NO: 928337-00-2
• Molecular Weight: 313.666
• Mol File: 928337-00-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6-chloro-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine(928337-00-2)
• EPA Substance Registry System: 6-chloro-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine(928337-00-2)

Safety Data

• Hazardous Substances Data: 928337-00-2(Hazardous Substances Data)

Usage

Molar Mass

Approximately 300.65 g/mol

Core Structure

Imidazo[1,2-b]pyridazine ring with a phenyl group attached

Functional Groups

Chlorine atom ( \textCl ) attached to the imidazo[1,2-b]pyridazine ring
Trifluoromethoxy group ( \textCF3\textO ) attached to the phenyl ring

Applications

Potential applications in pharmaceuticals
Potential applications in agrochemicals
Potential applications in materials science

Further Research

Needed to fully understand its properties and potential uses.

Upstream product

• 13526-66-4 3-bromo-6-chloro-imidazo[1,2-b]pyridazine 
• 179113-90-7 (3-(trifluoromethoxy)phenyl)boronic acid 

Downstream Products

• 1361951-26-9 2-(dimethylamino)-1-(4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-1-yl)ethanone 
• 1361950-89-1 2-methyl-4-((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)butan-2-ol 
• 1361950-92-6 2-methyl-1-((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)propan-2-ol 
• 1361950-98-2 4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)tetrahydro-2H-thiopyran 1,1-dioxide 
• 1361951-03-2 N-((tetrahydro-2H-thiopyran-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 
• 1361951-02-1 N-((4,4-difluorocyclohexyl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 
• 1361951-04-3 N-((tetrahydro-2H-pyran-4-yl)methyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 
• 1361951-07-6 1-methyl-4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-4-ol 
• 1361951-59-8 tert-butyl 2-oxo-4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidine-1-carboxylate 
• 1361951-08-7 4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-2-one 
• 1361951-12-3 2-(4-(((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-yl)amino)methyl)piperidin-1-yl)ethanol 
• 1418142-61-6 6-((tetrahydro-2H-pyran-4-yl)methoxy)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine 
• 1361951-25-8 N-(2-morpholinoethyl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-amine 
• 1025065-76-2 cyclopropyl-(4-((3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazin-6-ylamino)methyl)piperidin-1-yl)methanone 

Relevant articles and documents

SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3

The present invention relates to compounds of formula (I) and compositions comprising the same. The compounds and compositions may be used treat, prevent or ameliorate diseases treatable by inhibition of the Lemur tyrosine kinase 3 (LMTK3), such as cancer.

HETEROCYCLIC PROTEIN KINASE INHIBITORS

The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.

IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS

The present invention provides protein kinase inhibitors comprising imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine compounds of the following structure (I) and (II), or a stereoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein R, R1, R2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer and other Pim kinase-associated conditions are also disclosed.